Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Files for $100 Million IPO on the NASDAQ Exchange

publication date: Oct 30, 2019

I-Mab, a Shanghai biopharma, has filed to IPO on the NASDAQ Exchange with the goal of raising up to $100 million. The company was formed in 2017 when Third Venture Biopharma merged with Tasgen Biotech and completed a $150 million initial funding, led by C-Bridge Capital and Shanghai Tasly Pharma. Currently, I-Mab is developing a portfolio of 11 biologics for oncology and inflammatory indications, including immunotherapies. Eight of its candidates are in clinical trials. In 2018, I-Mab closed a $220 million C financing, one of the largest ever for a China biopharma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here